Replies to post #112852 on Biotech Values

[BTH]

I think you're right, Don, about why Merck didn't PR the event. As you said, it will be interesting to see if they mention timelines for the NDA and if they mention Rida, at all, during their CC. I would assume meeting the endpoints is a big deal for them considering Rida is generally their first-line drug in their oncology pipeline - one would think this would be a good bit of success for them.

As you stated, they'll probably have a good bit of PR when the full data analysis is out (at ASCO?) with subsets, etc.